Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Retatrutide and NAD+: Brief Overview Retatrutide is an investigational triple agonist that engages the GIP, GLP-1, and glucagon receptors, developed by Eli Lilly and still in Phase 3 trials
They are prepared using active ingredients under the direction of a prescribing clinician
Biology of incretins
Weight loss plateaus are common, even when using GLP-1 medications
Since the formula focuses exclusively on the microbiome pathway, it doesnt address other aspects of weight management like blood sugar regulation, insulin sensitivity, or mood and craving
Through the Bridge, qualifying Part D enrollees can access certain GLP-1 medications for weight management, including Foundayo , Wegovy (both injectable and pill), and the KwikPen formulation of Zepbound
